New hope for tough breast cancer: drug cocktail targets resistant tumors
NCT ID NCT02593175
First seen Nov 06, 2025 · Last updated Jun 22, 2026 · Updated 39 times
Summary
This phase II trial tested a combination of panitumumab (a targeted therapy) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery to women with triple-negative breast cancer that didn't respond to standard chemo. The goal was to shrink tumors and reduce the amount of tissue needing removal. The study enrolled 43 participants with early-stage breast cancer and measured how many had no cancer left at surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIA BREAST CANCER AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
panitumumab, carboplatin, and paclitaxel
What this could lead to
If successful, this combination could shrink tumors before surgery, potentially improving outcomes for people with triple-negative breast cancer that doesn't respond to standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 43 participants, so results may not apply to everyone. The drugs can cause side effects like low blood counts, nerve damage, and skin reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.